Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients
Objectives: The aim of this study was to evaluate the in vitro effects and clinical efficacies of trimethoprim-sulfamethoxazole (SXT) combined with other antimicrobial agents against Stenotrophomonas maltophilia. Methods: In vitro analysis was conducted on 89 S. maltophilia strains isolated from blo...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-05-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971217300681 |
_version_ | 1818606538856595456 |
---|---|
author | Hideki Araoka Masaru Baba Chikako Okada Masahiro Abe Muneyoshi Kimura Akiko Yoneyama |
author_facet | Hideki Araoka Masaru Baba Chikako Okada Masahiro Abe Muneyoshi Kimura Akiko Yoneyama |
author_sort | Hideki Araoka |
collection | DOAJ |
description | Objectives: The aim of this study was to evaluate the in vitro effects and clinical efficacies of trimethoprim-sulfamethoxazole (SXT) combined with other antimicrobial agents against Stenotrophomonas maltophilia.
Methods: In vitro analysis was conducted on 89 S. maltophilia strains isolated from blood and the respiratory tract between June 2012 and October 2014. Levofloxacin (LVX), ticarcillin-clavulanic acid (TIM), and minocycline (MIN) were selected for an examination of their effects when individually combined with SXT by the checkerboard method. In addition, 29 S. maltophilia bacteremia cases were reviewed and the clinical efficacies of SXT-based combination therapies were analyzed.
Results: SXT + LVX showed synergy in 21, no interactions in 61, and antagonism in 7. SXT + TIM showed synergy in 71, and no interactions in 18. SXT + MIN showed synergy in 10, and no interactions in 79. The review of clinical data indicated that a combination of SXT + fluoroquinolone was not associated with improved prognosis compared with monotherapy.
Conclusions: The in vitro data indicated that SXT + TIM had beneficial microbiological effects and was not antagonistic. Our in vitro and clinical data analyses do not support the routine use of SXT + fluoroquinolone combination therapy for S. maltophilia infection. |
first_indexed | 2024-12-16T14:12:27Z |
format | Article |
id | doaj.art-51fb53521a774fcaa34f34733c4ad6a2 |
institution | Directory Open Access Journal |
issn | 1201-9712 1878-3511 |
language | English |
last_indexed | 2024-12-16T14:12:27Z |
publishDate | 2017-05-01 |
publisher | Elsevier |
record_format | Article |
series | International Journal of Infectious Diseases |
spelling | doaj.art-51fb53521a774fcaa34f34733c4ad6a22022-12-21T22:28:43ZengElsevierInternational Journal of Infectious Diseases1201-97121878-35112017-05-0158C182110.1016/j.ijid.2017.02.020Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patientsHideki Araoka0Masaru Baba1Chikako Okada2Masahiro Abe3Muneyoshi Kimura4Akiko Yoneyama5Department of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanDepartment of Infectious Diseases, Toranomon Hospital, Tokyo, JapanObjectives: The aim of this study was to evaluate the in vitro effects and clinical efficacies of trimethoprim-sulfamethoxazole (SXT) combined with other antimicrobial agents against Stenotrophomonas maltophilia. Methods: In vitro analysis was conducted on 89 S. maltophilia strains isolated from blood and the respiratory tract between June 2012 and October 2014. Levofloxacin (LVX), ticarcillin-clavulanic acid (TIM), and minocycline (MIN) were selected for an examination of their effects when individually combined with SXT by the checkerboard method. In addition, 29 S. maltophilia bacteremia cases were reviewed and the clinical efficacies of SXT-based combination therapies were analyzed. Results: SXT + LVX showed synergy in 21, no interactions in 61, and antagonism in 7. SXT + TIM showed synergy in 71, and no interactions in 18. SXT + MIN showed synergy in 10, and no interactions in 79. The review of clinical data indicated that a combination of SXT + fluoroquinolone was not associated with improved prognosis compared with monotherapy. Conclusions: The in vitro data indicated that SXT + TIM had beneficial microbiological effects and was not antagonistic. Our in vitro and clinical data analyses do not support the routine use of SXT + fluoroquinolone combination therapy for S. maltophilia infection.http://www.sciencedirect.com/science/article/pii/S1201971217300681Stenotrophomonas maltophiliacombination therapytrimethoprim-sulfamethoxazolefluoroquinolonesticarcillin-clavulanic acidcancer patients |
spellingShingle | Hideki Araoka Masaru Baba Chikako Okada Masahiro Abe Muneyoshi Kimura Akiko Yoneyama Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients International Journal of Infectious Diseases Stenotrophomonas maltophilia combination therapy trimethoprim-sulfamethoxazole fluoroquinolones ticarcillin-clavulanic acid cancer patients |
title | Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients |
title_full | Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients |
title_fullStr | Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients |
title_full_unstemmed | Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients |
title_short | Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients |
title_sort | evaluation of trimethoprim sulfamethoxazole based combination therapy against stenotrophomonas maltophilia in vitro effects and clinical efficacy in cancer patients |
topic | Stenotrophomonas maltophilia combination therapy trimethoprim-sulfamethoxazole fluoroquinolones ticarcillin-clavulanic acid cancer patients |
url | http://www.sciencedirect.com/science/article/pii/S1201971217300681 |
work_keys_str_mv | AT hidekiaraoka evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients AT masarubaba evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients AT chikakookada evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients AT masahiroabe evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients AT muneyoshikimura evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients AT akikoyoneyama evaluationoftrimethoprimsulfamethoxazolebasedcombinationtherapyagainststenotrophomonasmaltophiliainvitroeffectsandclinicalefficacyincancerpatients |